# NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

> **NCT01393600** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 37 (actual)

## Conditions studied

- Tardive Dyskinesia

## Interventions

- **DRUG:** NBI-98854
- **DRUG:** NBI-98854
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01393600
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393600, "NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT01393600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*